Growth Disorders - Pipeline Review, H1 2012

Global Markets Direct, February 2012, Pages: 71

Growth Disorders – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Growth Disorders - Pipeline Review, H1 2012', provides an overview of the Growth Disorders therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Growth Disorders. 'Growth Disorders - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Growth Disorders.
- A review of the Growth Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Growth Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Growth Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Growth Disorders pipeline depth and focus of Growth Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Growth Disorders Therapeutic Products under Development, Key Players in Growth Disorders Therapeutics, Growth Disorders Pipeline Overview, Growth Disorders Pipeline, Growth Disorders Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Growth Disorders Overview
Therapeutics Development
An Overview of Pipeline Products for Growth Disorders
Growth Disorders Therapeutics under Development by Companies
Growth Disorders Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Growth Disorders Therapeutics – Products under Development by Companies
Growth Disorders Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Growth Disorders Therapeutics Development
Ipsen S.A.
Hanmi Pharmaceutical Co Ltd
Access Pharmaceuticals, Inc.
Biovitrum AB
Flamel Technologies S.A.
Hanall Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.
Physica Pharma
Synageva BioPharma Corp.
USV Limited.
PharmaEssentia Corporation
Ascendis Pharma A/S
Growth Disorders – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
rHGH + rIGF-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hGH XL - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHY 202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P1118 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SBC-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JR-401S - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACP-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vitatropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kiobrina - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genotropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Growth Hormone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CobOral hGH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Somatropin For Injection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HM10560A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Growth Disorders Therapeutics – Drug Profile Updates
Growth Disorders Therapeutics – Discontinued Products
Growth Disorders Therapeutics - Dormant Products
Growth Disorders – Product Development Milestones
Featured News & Press Releases
Jan 03, 2012: BioMarin To Initiate Phase I Trial In BMN-111 For Treatment Of Achondroplasia
Sep 27, 2011: Biopartners And LG Life Sciences Present Positive Phase III, 24 Months Efficacy And Safety Data For LB03002 Given To Children With Growth Hormone Deficiency
Aug 02, 2011: Swedish Orphan Biovitrum Announces First Patient Enrollment In Kiobrina Phase III Study
Jun 15, 2011: Antisense Therapeutics Receives Approval To Commence Phase I Clinical Trial Of ATL1103
Jun 09, 2011: ANP Receives Funding To Complete Additional Key Studies On ATL1103
Feb 21, 2011: Antisense Therapeutics Announces Final Preparations For ATL1103 Clinical Trial
Oct 04, 2010: Versartis Presents Positive Preclinical Data On Long-Acting Growth Hormone At International Congress Of GRS And IGF Society
Sep 27, 2010: PROLOR Biotech To Present hGH-CTP Data At International Congress Of Growth Hormone Research Society And IGF Society
Jun 20, 2010: Versartis Presents Positive Study Results Of VRS-317 At ENDO 2010
Mar 29, 2010: Versartis To Present New Data On Diabetes Drug At International Congress On Endocrinology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Growth Disorders, H1 2012
Products under Development for Growth Disorders – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Ipsen S.A., H1 2012
Hanmi Pharmaceutical Co Ltd, H1 2012
Access Pharmaceuticals, Inc., H1 2012
Biovitrum AB, H1 2012
Flamel Technologies S.A., H1 2012
Hanall Pharmaceutical Co., Ltd., H1 2012
JCR Pharmaceuticals Co., Ltd., H1 2012
Physica Pharma, H1 2012
Synageva BioPharma Corp., H1 2012
USV Limited., H1 2012
PharmaEssentia Corporation, H1 2012
Ascendis Pharma A/S, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Growth Disorders Therapeutics – Drug Profile Updates
Growth Disorders Therapeutics – Discontinued Products
Growth Disorders Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Growth Disorders, H1 2012
Products under Development for Growth Disorders – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Sleep Disorders – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Premature Ejaculation – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013